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Deletion, rearrangement, or amplification of sequences mapping to chromosome 8 are frequently observed in human prostate
and other tumors. However, it is not clear whether these events alter the transcriptional activity of the affected genes. To
examine this question, we have utilized oligonucleotide microarray technology and compared the transcriptional patterns of
normal human prostate tissues and five immortalized cell lines carrying either two normal chromosomes 8 or one normal and
one derivative chromosome 8. Comparison of the transcriptional profiles of the tissues and cell lines identified 125 differen-
tially expressed transcripts specific to chromosome 8, with 46 transcripts mapping to 8p and 79 transcripts mapping to 8q.
The majority of genes mapping to 8p (44/46, 96%) were transcriptionally down-regulated in cells hemizygous for 8p, whereas
the majority of genes mapping to 8q (58/79, 73%) were up-regulated in cells carrying three copies of 8q. Moreover, hemizygous
alleles on 8p exhibited sub-haploinsufficient transcript levels for several genes that could be induced to haploinsufficient levels
under hypomethylating conditions, suggesting that epigenetic regulation is a common mechanism for gene silencing in cells
deleted for one copy of 8p. The results of these studies clearly demonstrate that alterations of gene copy number and tran-
scriptional activity are directly correlated in cell lines harboring derivative chromosomes 8, and that these events are com-
monly observed during cellular immortalization in vitro. VC 2005 Wiley-Liss, Inc.
INTRODUCTION
A PubMed search conducted in March 2005
identified 170 citations linking chromosome 8 and
human prostate cancer, the most citations for any
chromosome. Many of these studies have clearly
demonstrated that deletion, rearrangement, or
amplification of sequences mapping to chromo-
some 8 are frequently observed in human prostate
and other tumors (Bergerheim et al., 1991; Wolman
et al., 1992; Bova et al., 1993; Macoska et al., 1993,
1994; MacGrogan et al., 1994; Sakr et al., 1994;
Trapman et al., 1994; Bova et al., 1996). Several
studies have identified discrete or large deletions
of the short arm of chromosome 8, suggesting that
one or more tumor-suppressor genes critical for
prostate tumorigenesis map to 8p. Even so, only a
few genes have been identified thus far as candi-
date tumor-suppressor genes mapping to 8p,
including NKX3.1 at 8p21, LZTS1 at 8p22, and
MSR1 at 8p22 (He et al., 1997; Ishii et al., 1999; Xu
et al., 2002). Other studies have demonstrated
amplification for all or part of the long arm of chro-
mosome 8 in prostate tumors, suggesting that one
or more oncogenes important for prostate tumori-
genesis map to 8q (Macoska et al., 1994; Takahashi
et al., 1994). In particular, amplification of the
8q24.21 region harboring the MYC oncogene has
been implicated as an independent prognostic fac-
tor predictive for prostate tumor recurrence, meta-
stasis, and poor patient outcome (Jenkins et al.,
1997; Sato et al., 1999).
Although the studies cited above successfully
defined regions of genomic loss or gain involving
chromosome 8, they did not globally examine the
potential effects of these large dosage changes on
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the transcriptional levels of genes mapping to
these sequences. This deficiency can be addressed
by the use of high-throughput technologies, which
now permit the dual analysis of genomic and tran-
scriptional alterations in human tumors. Using
these techniques, we and our colleagues have
shown that reduction to hemizygosity and tran-
scriptional down-regulation for genes mapping to
8p is largely coincident in human prostate tumors
and that genes mapping within the 8p11–p12
amplicon are largely transcriptionally up-regulated
in three human breast cancer cell lines (Chaib
et al., 2003; Ray et al., 2004).
We now report the utilization of high-throughput
techniques for precisely ‘‘mapping’’ the transcrip-
tional levels of genes on 8p and 8q for normal and
derivative chromosomes 8 in normal human pros-
tate tissues and immortalized human prostate epi-
thelial cell lines. These studies show that altera-
tions of gene copy number and transcriptional
activity are directly correlated in cell lines harbor-
ing derivative chromosomes 8. Moreover, several
genes mapping to hemizygous alleles on 8p exhib-
ited sub-haploinsufficient transcript levels that
could be induced to haploinsufficient levels under
hypomethylating conditions, suggesting that epige-
netic regulation is a common mechanism for gene
silencing in cells deleted for one copy of 8p. Taken
together, these observations suggest that altera-
tions in copy number and transcriptional activity of
genes mapping to derivative chromosomes 8 are
associated with human prostate epithelial cellular
immortalization in vitro.
MATERIALS ANDMETHODS
Establishment of Cell Cultures
Normal prostate tissue samples were obtained
aseptically from patients undergoing radical prosta-
tectomy after cancer diagnosis. All tissue acquisi-
tion and processing protocols conformed to those
reviewed and approved by the University of Michi-
gan Institutional Review Board. The tissue was
minced into pieces < 1 mm2; one piece was fixed
in 5% formalin for further histopathological evalua-
tion, whereas the rest was plated into 60-mm plates
coated with Vitrogen 100 (Cohesion Laboratories,
Palo Alto, CA) in keratinocyte growth medium
supplemented with bovine pituitary extract, epi-
dermal growth factor (EGF), and antibiotics (Invi-
trogen, Carlsbad, CA). Cultures that exhibited
both fibroblastic and epithelial cell populations
were subjected to brief trypsinization for removal
of fibroblast cells. Cells were immortalized through
transduction with the recombinant LXSNE6E7
retrovirus harboring the human papilloma virus E6
and E7 genes as described previously (Bright et al.,
1997). Transduced cells were selected by use of
400 lg/ml geneticin. After an initial round of cell
death and crisis, cells resistant to geneticin grew
out and were considered immortal after 10 pas-
sages. Immortalized cell cultures were diluted 1:24
and individual subclones established. Selected
subclones were plated into sterile chamber slides,
grown to 80% confluency, fixed in 50% methanol/
50% acetic acid, and stained using a pan-cytokera-
tin monoclonal antibody mixture containing clones
C-11, PRK-26, CY-90, KS-1A3, M20, and A53-B/A2
for detection of epithelial cells, or a monoclonal
antivimentin antibody (Sigma-Aldrich, St. Louis,
MO) for detection of stromal fibroblastic cells. A
representative subclone homogenously staining
with the pancytokeratin antibodies but not the
antivimentin antibody was chosen from each cul-
ture for further analysis. Cells at the following pas-
sage numbers (where p indicates passage) were
used for all experiments: N15C6 early, < p25;
N15C6 late, > p40; N17A3, p25–p30; N33B2, p25–
p30; 1532T, p40–45; 1542T, p40–45.
Spectral Karyotyping Analysis
Spectral karyotyping (SKY) analysis was carried
out on previously G-banded slides. Images were
captured, and the microscope coordinates were
noted. Residual oil was removed with xylene, fol-
lowed by destaining with methanol. The slides
were then rehydrated in a descending ethanol ser-
ies and fixed with 1% formaldehyde in a 50 mM
MgCl2/phosphate buffer solution for 10 min. Slides
were dehydrated and denatured for 30–45 sec at
758C in 70% formamide/23 SSC (saline sodium
citrate), followed by a final dehydration. The SKY
paints (Applied Spectral Imaging, Carlsbad CA)
were denatured for 7 min at 758C, reannealed at
378C for 1 hr, and then placed on the slide and cov-
ered with a glass coverslip. The coverslip was
sealed with rubber cement, and hybridization was
carried out in a humidified chamber for 24 hr at
378C. Posthybridization washes were carried out
according to established techniques and according
to the manufacturer’s instructions (Shrock et al.,
1996). Images of metaphase chromosomes were
captured for each preparation by use of an SD 200
spectral bio-imaging system (ASI Ltd., Migdal
Haemek, Israel) attached to a Zeiss microscope
(Axioplan 2) and stored on a SKY image-capture
workstation. The passage number (p) and number
of metaphase images captured and analyzed [in
137DERIVATIVE CHROMOSOME 8 AND TRANSCRIPTION
Genes, Chromosomes & Cancer DOI 10.1002/gcc
brackets] were as follows for each cell line: N15C6
p20 [10]; N15C6 p45 [10]; N17A3 p26 [10]; N33B2
p21 [9]; 1532T p44 [10]; and 1542T p44 [10].
The images were analyzed with SKYView software
(Applied Spectral Imaging). G-banding and SKY
analyses were performed sequentially on each of
the cell lines with the same 10 metaphase images
captured for G-banding also analyzed by SKY.
SNPAnalysis
Cells were grown to 90% confluency. Genomic
DNA was harvested with use of the Wizard Genomic
Purification Kit (Promega Corp., Madison, WI) ac-
cording to the manufacturer’s protocol. Allelic discrim-
ination PCR was run by use of Assays on Demand
FAM and VIC-labeled probes (Applied Biosystems,
Foster City, CA) according to the manufacturer’s pro-
tocols, with 13.5 ng of genomic DNA as the template.
The specific SNP assays used were: RANBP16,
C__1959574_20; CSMD1, C__1423109_10; TACC1,
C_11861239_10; NEFL, C___322260_10; RBPMS,
C_15880850_10, andMSR1, C_12104846_10. All reac-
tions were performed in triplicate, and no-template
controls were included. Alleles for any locus (arbitra-
rily termed ‘‘A’’ or ‘‘B’’) were identified by the SNP
assays from averaged intensity values from triplicate
determinations after subtraction of no-template con-
trol values. The ratio of B/A was interpreted to indi-
cate two alleles at a given locus if 0.5< B/A< 1.5 (in-
dicative of both alleles, AB). One allele was assessed
if B/A > 1.5 (indicative of the B allele) or if B/A <
0.5 (indicative of the A allele).
Affymetrix U133AGeneChip Data Acquisition
RNA was purified from histologically verified
(>70% epithelial) normal human prostate tissues
from three separate specimens or from trypsinized
cultured cells by homogenization in Trizol (Invitro-
gen, Carlsbad, CA) and additional processing with
the RNeasy (Qiagen, Valencia, CA) cleanup proce-
dure. Ten micrograms of RNA obtained from tis-
sues or cell lines was used to obtain labeled cRNA.
Following an in vitro transcription reaction, the
labeled cRNAwas fragmented and then hybridized
to Affymetrix U133A GeneChips (Affymetrix,
Santa Clara, CA) for 16 hr at 458C. The array was
then washed and stained with streptavidin-phy-
coerythrin and scanned. Expression intensity val-
ues for each gene were estimated by a method
called robust multiarray average (RMA), which is
implemented in the Affymetrix library of the Bio-
conductor package for the statistical language R.
This method uses a robust modeling strategy to
estimate the average intensity of each gene on
each chip. Detailed information can be found at
http://www.bioconductor.org. GeneChip expression
values were analyzed by use of a t-test-based analy-
sis adjusted for false discovery rate (FDR) with the
Significance Analysis of Microarrays (SAM) pro-
gram (Tusher et al., 2001). The resulting data were
organized by use of a hierarchical clustering
scheme for grouping genes with similar expression
patterns (Eisen et al., 1998). The distance metric
used in the hierarchical clustering was the Pearson
correlation.
Quantitative Real-Time PCR
All quantitative real-time assays were conducted
with an Applied Biosystems 7900HT instrument
and reagents. One microgram of RNA was reverse-
transcribed by use of Superscript III reverse tran-
scriptase (Invitrogen, Carlsbad, CA). The resulting
cDNA was diluted 1:100. Real-time PCR was per-
formed by use of Assays on Demand (Applied Bio-
Systems, Foster City, CA) according to the manufac-
turer’s instructions, except that Real Time Ready
with Rox passive dye (QBioGene, Carlsbad, CA)
was used in place of TaqMan Universal PCRMaster
Mix. The FAM-conjugated, gene-specific assays
were as follows: TNKS, Hs00186671_ml; MTUS1,
Hs00368183_m1; NKX3.1, Hs00171834_m1; CLU,
Hs00156548_m1; RBPMS, Hs00199302_m1; RCP,
0368787_m1; PPP2CB, Hs00602137_ml; TACC1,
Hs00180691_ml; MYST3, Hs00198899_ml; IKBKB,
Hs00395088_ml; RGS20, Hs00186596_m1; SNAI2,
Hs00161904_m1; UBE2V2, Hs00163342_m1; MATN2,
Hs00242767_m1, and the controlRPLPO, Hs99999902_m1.
Methylation Block
Cells were grown to 50% confluency, then
treated for 5 days with 5 lM 5Aza-2-dCTP in 50%
acetic acid (Sigma-Aldrich, St. Louis, MO) or ace-
tic acid alone (50 ll in 5 ml of medium; Mock
treatment) in triplicate (Yamashita et al., 2002).
RNA was prepared, and transcript levels for spe-
cific genes were assessed by use of quantitative
real-time PCR. Statistical analysis was performed
by ANOVA by use of averaged experimental
(5Aza-dC) minus control (acetic acid) values.
RESULTS
The Majority of Immortalized Prostate Epithelial
Cells Exhibit 8p Loss
Five cell lines were successfully developed from
normal prostate epithelium through transduction
with the pLXSN16E6E7 recombinant retrovirus.
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Development and characterization of the 1532T,
1542T, and N15C6 cell lines were reported previ-
ously (Bright et al., 1997; Macoska et al., 2000,
2004; Schwab et al., 2000). The N17A3 and N33B2
cell lines are described here for the first time. The
karyotypes for the 1532T, 1542T, and N15C6 cell
lines have been reported elsewhere (Macoska
et al., 2000, 2004). The karyotypes for the remain-
ing two cell lines are as follows: N17A3 (at passage
26, 10 cells analyzed), 34–48,X,Y, 11 (8/9 cells),
19 (7/9 cells), þ20 (8/9 cells), 22 (8/9 cells),
der(15)t(11;15)(q14;q24) (5/9 cells); and N33B2 (at
passage 21, 9 cells analyzed), 40–44,X,Y, 19 (4/7
cells), 22 (5/7 cells), der(1)t(1;13)(p36;q32) (6/7
cells), i(8q) (5/7 cells), der(13)t(11;13)(p10;q10) (2/
7 cells), der(15)t(15;19)(q10;p10) (3/7 cells).
Two cell lines—N15C6 and 1542T—exhibited
structural alterations of chromosome 8 that inclu-
ded translocation of chromosome 8 sequences to
19p (N15C6), 20q (1542T), or 21q (1542T). Three
cell lines—1532T, 1542T, and N33B2—exhibited
i(8q) chromosomes. Four of the six cell lines were
hemizygous for the short arm of chromosome 8
(8p). The configuration of chromosomes 8 in each
of the five cell lines is detailed in Table 1 and
shown in Figure 1. Only the N17A3 cell line dem-
onstrated two normal chromosomes 8. SNP analy-
sis confirmed hemizygosity for all six SNP loci
examined on 8p in the N33B2, N15C6, 1532T, and
1542T cell lines and heterozygosity for the MSR1,
NEFL and TACC1 loci on 8p in the N17A3 cell line
(Table 2).
Gene Transcript Levels Are Proportional to Gene
Dosage on Chromosome 8
GeneChip expression values were compared
between samples demonstrating two normal chro-
mosomes 8 (the three normal prostate tissues and
N17A3 cells) and those demonstrating derivative
chromosomes 8 (N33B2, N15C6, 1532T, and
1542T cells) by use of a t-test-based analysis
adjusted for FDR with the Significance Analysis
of Microarrays program. The FDR is equivalent
to the q value and is indicated as the q value in Fig-
ure 2. The FDR ranged from 0.03% to 5.0%.
These analyses identified 125 differentially ex-
pressed transcripts specific to chromosome 8, with
46 localized to genes mapped to 8p and 79 local-
ized to genes mapped to 8q. The majority of tran-
scripts mapping to 8p (44/46, 96%) were signifi-
cantly down-regulated in cells carrying derivative
chromosomes 8, and was consistent with reduction
to hemizygosity for 8p in the N15C6, N33B2,
1532T, and 1542T cell lines. This comparison also
demonstrated that the majority of transcripts map-
ping to 8q (58/79, 73%) were significantly up-regu-
lated in cells carrying derivative chromosomes
8 (Fig. 2) compared to N17A3 cells and normal
tissues.
To examine further the relationship of 8q dosage
to 8q gene transcript levels, we performed an addi-
tional SAM analysis that focused exclusively on
the transcriptional levels of genes mapping to 8q.
For these experiments, transcript levels for 8q
genes were compared for N15C6 and N17A3 cells
(both carrying 2 copies of 8q) with N33B2 and
1532T cells (both carrying 3 copies of 8q). This
analysis identified 41 differentially expressed
genes on 8q, with 34/41 (83%) up-regulated in
N33B2 and 1532T cells compared to N17A3 and
N15C6 cells. The results of these studies are con-
sistent with a concordant increased transcriptional
level and increased gene dosage for genes mapping
to 8q in N33B2 and 1532Tcells.
When organized by use of an unsupervised hier-
archical clustering scheme with genes ordered
based on chromosomal position (8pter–8qter), the
gene expression data formed two large clusters,
TABLE 1. Chromosome 8 Configuration in HPV-Immortalized Cell Lines




copies of 8q Reference
N17A3 two normal 2 2 This study
1532T one normal, one i(8)(q10) 1 3 Macoska et al., 2000
1542T one i(8)(8q10), one der(8;20)(q10;p10), or
one der(8;21)(q10;p10)
1 3 Macoska et al., 2000
N33B2 one normal, one i(8)(q10) 1 3 This study
p20: one normal,
one der(8)t(8;19)(q10;p10),
two der(8)t(8;20)(p10;q10) 2 2
N15C6 p45: one normal, one der(8;19)(q10;q10) 1 2 Macoska et al., 2004
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one comprising the three normal tissues and the
N17A3 cells, which carried two normal chromo-
somes 8, and the other comprising the N33B2,
N15C6, 1532T, and 1542T cells, which carried
derivative chromosomes 8 (Fig. 2). This result
demonstrated that the observed trends in gene
expression identified by the transcriptional profiles
were largely consistent with the physical structure
(normal or derivative) of the chromosomes 8 of the
evaluated tissue or cell line. It should be noted that
a large block of genes localized pericentromerically
on 8q11 were transcriptionally up-regulated in
N33B2, 1532T, and 1542T, the three cell lines that
were hemizygous for 8p and carrying i(8q) chromo-
somes (Fig. 2).
Transcript Levels Are Frequently Reduced to
Sub-Haploinsufficient Levels in Cells Hemizygous
for 8p
The transcriptional levels of 14 genes—10
mapped to 8p (TNKS, MTUS1, NKX3.1, CLU,
RBPMS, RCP, PP2CB, TACCI, MYST3, IKBKB)
and 4 mapped to 8q (RGS20, SNAI2, UBE2V2,
MATN2)—identified as differentially expressed in
the GeneChip experiments were assessed by quan-
titative real-time PCR. As seen in Table 3, the
expression trends for genes evaluated by both
GeneChip and real-time PCR methodologies were
similar. All 10 genes mapping to 8p were trans-
Figure 1. Spectral karyotype
analysis of derivative chromosomes
8 in immortalized human prostate
epithelial cells. Chromosomes are
shown both before (G-banded, left)
and after (pseudo-color application,
right) hybridization with whole-
chromosome paint probes. The
compositions of derivative chromo-
somes 8 are indicated. Pseudo col-
oring indicates chromosome 8 in
orange, chromosome 20 in blue;
chromosome 21 in yellow, and chro-
mosome 19 in green.
TABLE 2. SNPAllelotyping of Prostate Cell Lines
Locus
Cell line
N17A3 N33B2 N15C6 1532T 1542T
CSMD A A B B B
MSR1 AB B B A B
NEFL AB A B B B
RAN B A A A A
RBPMS A B A A A
TACC1 AB A B A A
Alleles at a locus have been designated as ‘‘A’’ or ‘‘B’’ according to these
criteria: hemizygous for B when B/A > 1.5, hemizygous for A when B/A
< 0.5, and heterozygous when 0.5 < B/A < 1.5.
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Figure 2. Hierarchical clustering
of chromosome 8 molecular signa-
tures for prostate tissues and cell
lines. Normal human prostate tis-
sues and the N17A3 immortalized
human prostate epithelial cell line
carry two normal chromosomes 8,
whereas the N33B2, 1542T, N15C6,
and 1532T immortalized human
prostate epithelial cell lines carry
derivative chromosomes 8. Normal
human prostate tissues and the
N17A3 cell cluster together on the
left; the N33B2, 1542T, N15C6, and
1532T cell lines cluster together on
the right of the diagram. Differen-
tially expressed genes are desig-
nated by GenBank accession num-
bers and are arranged according to
chromosomal position, from 8pter
(top) to 8qter (bottom). Relative gene
expression intensities are represented
by color, with the highest expression
indicated by light red and lowest
expression by light green (see color
bar). The data columns to the right of
the heat map indicate the GenBank
accession number, t statistic, -fold
change, q value (false discovery rate),
physical location on chromosome 8
in base pairs relative to 8pter (at 0),
and expression trend for each gene.
The physical location of the indicated
genes is shown with reference to the
chromosome 8 ideogram on the left.
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TNKS 8p23.1 N17A3 8.5349 Normal diploid 1.27 (0.16)
N15C6 7.5549 0.51 0.22 Haploinsufficient 0.84 (0.42)
N33B2 7.5700 0.51 0.09 Haploinsufficient 1.03 (0.57)
1532T 7.4964 0.50 0.50 Haploinsufficient 0.76 (0.08)
1542T 7.6001 0.52 0.45 Haploinsufficient 0.99 (1.48)
MTUS1/ATIP/MTSG1
8p22
N17A3 9.0427 Normal diploid 1.09 (0.10)
N15C6 8.1129 0.52 0.53 Haploinsufficient 0.84 (0.02)
N33B2 7.0428 0.25 0.51 Sub-haploinsufficient 0.90 (0.07)
1532T 7.2312 0.28 0.62 Sub-haploinsufficient 0.81 (0.03)
1542T 7.1544 0.27 0.52 Sub-haploinsufficient 0.94 (0.04)
NKX3.1 8p21.2 N17A3 8.7627 Normal diploid 0.96 (0.10)
N15C6 7.6702 0.47 0.42 Haploinsufficient 0.93 (0.01)
N33B2 7.4763 0.41 0.59 Haploinsufficient 1.03 (0.01)
1532T 7.5506 0.43 0.62 Haploinsufficient 0.93 (0.00)
1542T 7.5211 0.42 0.46 Haploinsufficient 0.99 (0.16)
CLU 8p21.1 N17A3 9.7010 Normal diploid 1.18 (0.02)
N15C6 7.8431 0.28 0.23 Sub-haploinsufficient 1.38 (0.01)
N33B2 7.8727 0.28 0.65 Sub-haploinsufficient 1.20 (0.04)
1532T 7.6853 0.25 0.42 Sub-haploinsufficient 1.15 (0.14)
1542T 8.0263 0.29 0.33 Sub-haploinsufficient 0.97 (0.09)
RBPMS 8p12 N17A3 7.8116 Normal diploid 1.17 (0.96)
N15C6 6.5243 0.41 0.31 Haploinsufficient 1.44 (0.31)
N33B2 6.6881 0.46 0.80 Haploinsufficient 1.14 (0.49)
1532T 7.0163 0.58 0.31 Haploinsufficient 1.13 (0.07)
1542T 6.7768 0.49 0.39 Haploinsufficient 1.35 (0.07)
RCP 8p12 N17A3 8.9545 Normal diploid 0.77 (0.09)
N15C6 8.0395 0.53 0.58 Haploinsufficient 0.99 (0.10)
N33B2 6.7461 0.22 0.31 Sub-haploinsufficient 1.00 (0.08)
1532T 6.7558 0.22 0.26 Sub-haploinsufficient 0.93 (0.09)
1542T 7.0416 0.27 0.06 Sub-haploinsufficient 0.83 (0.03)
PPP2CB 8p12 N17A3 11.4297 Normal diploid 0.84 (0.17)
N15C6 11.1333 0.81 0.33 Haploinsufficient 1.03 (0.48)
N33B2 10.8176 0.65 0.40 Haploinsufficient 0.66 (0.01)
1532T 10.6311 0.57 0.40 Haploinsufficient 1.25 (0.92)
1542T 10.9211 0.70 0.19 Haploinsufficient 1.60 (0.22)
TACC1 8p11.23 N17A3 8.7967 Normal diploid 1.80 (0.11)
N15C6 7.8278 0.51 0.50 Haploinsufficient 1.08 (0.14)
N33B2 8.2347 0.68 0.02 Haploinsufficient 1.61 (0.96)
1532T 7.8839 0.53 0.80 Haploinsufficient 1.50 (1.07)
1542T 8.4415 0.78 0.84 Elevated 0.67 (0.20)
MYST3 8p11.21 N17A3 10.3441 Normal diploid 0.82 (0.09)
N15C6 9.9824 0.78 0.51 Haploinsufficient 1.23 (0.50)
N33B2 9.5280 0.57 0.27 Haploinsufficient 0.90 (0.07)
1532T 9.3938 0.52 0.26 Haploinsufficient 1.18 (0.06)
1542T 9.4300 0.53 0.54 Haploinsufficient 1.89 (0.36)
IKBKB 8p11.21 N17A3 7.3251 Normal diploid 0.99 (0.08)
N15C6 6.6220 0.61 0.43 Haploinsufficient 1.09 (0.02)
N33B2 6.6027 0.61 0.41 Haploinsufficient 1.03 (0.05)
1532T 6.4703 0.55 0.33 Haploinsufficient 1.13 (0.03)
1542T 6.6620 0.63 0.56 Haploinsufficient 1.08 (0.05)
RGS20 8q11.23 N17A3 6.4388 1.08 (0.08)
N15C6 7.3215 1.84 1.47 1.20 (0.08)
N33B2 8.7131 4.84 1.90 1.05 (0.03)
1532T 8.0973 3.16 1.85 1.16 (0.02)
1542T 8.7364 4.92 15.38 1.22 (0.06)
SNAI2 8q11.21 N17A3 9.3423 1.10 (0.31)
N15C6 11.2486 3.75 1.12 2.68 (0.14)
N33B2 11.8038 5.51 9.88 1.84 (0.15)
(Continued)
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criptionally down-regulated in the majority of cell
lines hemizygous for 8p, compared to those hetero-
zygous for 8p. However, the transcriptional profiles
for each gene in each cell line hemizygous for 8p
were somewhat heterogeneous and varied from
haploinsufficient or sub-haploinsufficient levels
to elevated levels. For example, after normaliza-
tion to N17A3 transcript levels as a measure of
normal heterozygous transcriptional activity, it was
apparent that all cell lines hemizygous for 8p
expressed NKX3.1 at haploinsufficient levels,
that is, between 0.41- and 0.47-fold of that ob-
served for N17A3 cells by GeneChip analysis. In
contrast, all cells hemizygous for 8p expressed
CLU at sub-haploinsufficient levels, between 0.25-
and 0.29-fold of that observed for N17A3 cells.
TNKS, MTUS1, RBPMS, RCP, and IKBKB were
expressed at haploinsufficient or sub-haploinsuffi-
cient levels in cells hemizygous for 8p. Expression
levels of PP2CB, TACC1, and MYST3 were haploin-
sufficient for three of four cell lines hemizygous for
8p, but were elevated, that is, expressed at near-
heterozygous levels, in one of the four cell lines
(Table 3). In total, transcript levels were measured
in 40 instances (4 cell lines hemizygous for 8p, 10
genes evaluated by quantitative real-time PCR)
and were found to be haploinsufficient in 27/40
instances (68%), sub-haploinsufficient in 10/40
instances (25%), and elevated in 3/40 instances
(8%) by GeneChip analysis. These observations
demonstrate that transcript levels were reduced to
haploinsufficient or sub-haploinsufficient levels in
the majority (37/40, 92%) of the cases examined in
this study.
Epigenetic Mechanisms May Regulate Transcription
of Hemizygous 8p Genes
The observed sub-haploinsufficient transcript
levels for three genes—MTUS1, CLU, and RCP—
mapping to 8p in cells hemizygous for the same
sequences could be attributed to epigenetic mech-
anisms. To investigate this question, we grew cells
heterozygous (N17A3) or hemizygous (N15C6,
N33B2, 1532T, 1542T) for 8p in the presence of
the methylation blocking agent 5Aza-2-dCTP or,
as a control, in the vehicle solvent acetic acid. Of
the 10 genes examined, exposure to the methyla-
tion blocking agent was associated with signifi-
cantly increased transcript expression of MTUS1,
CLU, and RCP in three or more cell lines hemizy-
gous for 8p (Table 3). For genes mapping to 8q,
none of the three genes that exhibited increased
transcript levels compared to N17A3 cells by Gene
Chip and quantitative RT-PCR analyses demon-
strated significantly higher expression levels in
more than two cell lines after treatment with the
hypomethylating agent. In contrast, MATN2, which
maps to 8q but exhibited decreased transcript lev-
els compared to N17A3 cells by both gene expres-
sion profiling and quantitative RT-PCR studies,
demonstrated significantly increased transcript lev-
els in N15C6, N33B2, and 1542T cells after treat-
ment with 5Aza-2-dCTP (Table 3). These data
suggest that both allelic deletion and sequence




















1532T 11.3941 4.15 1.03 1.57 (0.12)
1542T 11.9651 6.16 8.26 0.64 (0.04)
UBE2V2 8q11.21 N17A3 8.9640 1.16 (0.21)
N15C6 10.0513 2.12 2.73 1.35 (0.12)
N33B2 10.3167 2.55 2.09 1.31 (0.08)
1532T 9.8244 1.82 1.78 1.74 (0.09)
1542T 10.4446 2.79 1.00 1.84 (0.27)
MATN2 8q22 N17A3 9.4594 0.70 (0.04)
N15C6 6.2641 0.11 0.82 0.77 (0.02)
N33B2 6.4067 0.12 0.20 0.84 (0.04)
1532T 8.5334 0.53 0.12 0.79 (0.02)
1542T 6.7616 0.15 0.30 0.81 (0.02)
aGene symbol and cytogenetic location are shown.
bN17A3 cells possess two copies of 8p, whereas N15C6, N33B2, 1532T, and 1542T cells possess one copy of 8p.
cFor cells with one copy of 8p, haploinsufficient levels are defined as between 0.70 and 0.30 of normal, sub ¼ haploinsufficient as < 0.30 of normal, and
elevated as > 0.70 of normal.
dGene expression is expressed as a ratio of that obtained for cells grown in 5 mM 5-Aza-2-dCTP and that for mock-treated cells (standard deviation is
shown in parentheses).
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methylation may contribute to the transcriptional
silencing of particular genes in immortalized and
initially transformed human prostate cells.
DISCUSSION
Loss of 8p and gain of 8q are observed fre-
quently in human prostate tumors. These observa-
tions are consistent with the hypothesis that
tumor-suppressor genes mapping to 8p and onco-
genes mapping to 8q play critical roles in prostate
cellular immortalization and transformation. How-
ever, identifying specific genes that function as
tumor-suppressor genes or oncogenes mapping to
chromosome 8 has been difficult and labor inten-
sive. We have attempted to address these issues by
utilizing a high-throughput approach to identifying
candidate tumor-suppressor genes and oncogenes
associated with DNA sequences losses or gains,
respectively, on chromosome 8.
Examination of the transcriptional profiles of
prostate tissues and cell lines possessing two normal
chromosomes 8 and of those possessing derivative
chromosomes 8 revealed large-scale transcriptional
up-regulation of genes mapping to 8q. Three of the
four cell lines exhibiting derivative chromosomes
8—N33B2, 1532T, and 1542T—carry i(8q) chromo-
somes with consequent gain of 8q. Moreover, spe-
cific ‘‘blocks’’ of increased gene transcription were
evident on the 8q arm. Notably, a large block of 20
genes localized pericentromerically on 8q was tran-
scriptionally up-regulated in the four cell lines carry-
ing derivative chromosomes 8 (Fig. 2). This sug-
gests that long-range chromatin modifications may
occur because of reduction to hemizygosity for 8p
that result in increased transcriptional activity of
pericentromeric genes. Other blocks of transcrip-
tionally up-regulated genes on 8q, including one at
8q22 and most of the 8q24 region, are consistent
with sites for putative oncogenes (Rubin, 2004;
Savinainen, 2004; Wang, 2004).
Four of the five immortalized prostate epithelial
cell lines utilized in the studies reported here were
hemizygous for 8p and demonstrated transcrip-
tional down-regulation for the majority (96%) of
genes mapping to 8p. These four cell lines clus-
tered with each other in the dendrogram shown in
Figure 2, suggesting that they shared a common
transcriptional molecular signature largely driven
by hemizygosity for 8p. In the majority (68%) of
cases examined, hemizygosity for 8p was associ-
ated with haploinsufficient transcript levels, that is,
levels that were approximately half that observed
for cells possessing two copies of 8p (Table 3).
However, an additional 25% of cases examined
demonstrated transcript levels that were further
reduced to sub-haploinsufficient levels (Table 3).
This finding suggested that some of the genes
mapping to the sole copy of 8p in these cells might
be transcriptionally inactivated through epigenetic
mechanisms. Indeed, induction of a methylation
block resulted in significantly increased expression
of all transcripts detected at sub-haploinsufficient
levels by GeneChip analysis. The results of these
studies clearly demonstrated that methylation-
mediated epigenetic regulation could be responsi-
ble for the observed sub-haploinsufficient 8p hemi-
zygous allele transcript levels in immortalized and
initially transformed prostate epithelial cells.
Surprisingly, transcripts originating from 8p
hemizygous alleles were actually elevated above
haploinsufficient levels in 3 of 40 (8%) of cases
examined. This phenomenon was largely heteroge-
neous, and was observed for three genes—
PPP2CB, TACC1, and MYST3—in one cell line
each. PPP2CB was recently found to be down-
regulated in a majority of prostate tumors exam-
ined but up-regulated in a minority of cases (Wiss-
mann et al., 2003). TACC1 has been described as
transcriptionally down- and up-regulated in human
breast tumors, the latter in conjunction with DNA
amplification (Conte et al., 2002; Ray et al., 2004).
Although transcript expression of MYST3 has not
been previously reported for prostate tissues,
MYST3 is involved in t(8;16)(p11;p13) transloca-
tions and forms a fusion protein with CREBBP that
is frequently associated with acute myeloid leuke-
mia (Rozman et al., 2004). A survey of gene expres-
sion profiles of normal and malignant prostate tis-
sues identified down-regulation forMYST3 in three
studies, up-regulation in one study, and lack of dif-
ferential expression in four other studies (http://
www.oncomine.org). These reports suggest that
these three genes in particular may be subject to
complex transcriptional and translational regulation
in human prostate cells.
The observation of both haploinsufficient and
sub-haploinsufficient transcript levels originating
from hemizygous alleles of 8p-localized genes fur-
ther suggests that deletion of one copy of 8p may
result in either a one-hit or a two-hit mechanism
for tumor initiation or progression. This hypothesis
proposes that cells suffering deletion of one copy
of 8p and expressing haploinsufficient levels of
associated transcripts may be preferentially selected
for clonal growth and immortalization, whereas
similar cells that experience further transcript re-
ductions to sub-haploinsufficient levels may be
driven further down the road of malignant progres-
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sion. This is a difficult hypothesis to test because
of the typical presence of several genetic altera-
tions in addition to 8p loss in cultured cells and
tumors. However, evaluation of the simple cul-
tured-cell models used in the current study showed
that N33B2, 1532T, and 1542Tcells exhibited sub-
haploinsufficient levels of 3 of the 10 genes exam-
ined on 8p, whereas N15C6 cells exhibited sub-
haploinsufficient levels of only 1 of the same 10
genes (Table 3). Moreover, previous studies have
shown that 1532T and 1542T cells express a more
advanced malignant phenotype than do N15C6 cells
(Schwab et al., 2000; Macoska et al., 2000, 2004).
Taken together, these observations are consistent
with a positive correlation between advanced ex-
pression of the malignant phenotype and sub-hap-
loinsufficient levels of hemizygous 8p gene tran-
script levels. This is an interesting hypothesis that
will require the study of more refined, gene-specific
models for thorough testing and evaluation.
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